

FISCAL NOTE

Bill #: HB0563

Title: Pharmaceutical market reform

Primary Sponsor: Dowell, T

Status: 2nd reading as amended

Sponsor signature

Date

David Ewer, Budget Director

Date

Fiscal Summary

	<u>FY 2006</u> <u>Difference</u>	<u>FY 2007</u> <u>Difference</u>
Expenditures:		
General Fund	\$0	\$0
Revenue:		
General Fund	\$0	\$0
Net Impact on General Fund Balance:	\$0	\$0

- | | |
|---|--|
| <input type="checkbox"/> Significant Local Gov. Impact | <input type="checkbox"/> Technical Concerns |
| <input type="checkbox"/> Included in the Executive Budget | <input type="checkbox"/> Significant Long-Term Impacts |
| <input type="checkbox"/> Dedicated Revenue Form Attached | <input type="checkbox"/> Needs to be included in HB 2 |

Fiscal Analysis

ASSUMPTIONS:

1. The bill allows for the Department of Justice to establish administrative rules to create the required reporting form for RX companies. Once the form is created, the only action by the department will be to make the form available to requesting RX companies. Including the form as a downloadable form from the Department of Justice web site will likely do this.
2. The bill requires Justice to collect reports and disseminate the information back to the Legislature and the Governor. Copies of the submitted reports will be sent to these offices. Assuming all RX companies complete the reports the requirements of the department remain ministerial.
3. At this time, the department is not able to determine the number of non-compliant RX companies, and therefore it is unknown the amount of penalties that may be collected. Actions brought by the department for non-reporting RX companies would be handled by the Legal Services Division.
4. Based on the above assumptions, the Department of Justice will absorb all costs associated with this legislation within current level budget.